The pituitary cancer market involves the treatment of rare cancer that develops in the pituitary gland located at the base of the brain. Pituitary cancer accounts for nearly 1% of all intracranial tumors and is mainly caused due to genetic mutations. The conventional treatment options for pituitary cancer include surgery, radiation therapy, chemotherapy, targeted drug therapy, and hormone therapy. Surgery remains the primary treatment approach as it helps remove the tumor whereas targeted drug therapy and hormone therapy are commonly prescribed for controlling hormonal imbalances caused by pituitary tumors.
The global pituitary cancer market is estimated to be valued at US$ 457.31 Mn in 2024 and is expected to exhibit a CAGR of 9.6% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the pituitary cancer market are Novartis International AG, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Endocyte, RECORDATI GROUP, Camurus AB, Endeavor Biomedicines, Inc., and Debiopharm International SA. These companies are majorly focused on developing targeted therapeutics and hormone therapies for pituitary cancer treatment. For instance, Novartis AG offers Sandostatin for treating hormonally active pituitary tumors.
The Pituitary Cancer Market Demand considerably owing to the rising prevalence of pituitary tumors worldwide. According to the National Organization for Rare Diseases, pituitary adenomas occur in nearly 1 in 1,000 people. The increasing R&D activities to develop advanced targeted therapies and hormone replacement drugs are also fostering market growth.
Technological advancements in the field of genomics and bioinformatics have enabled researchers to better understand the molecular mechanisms responsible for pituitary tumor development. This has facilitated the development of targeted therapies that act on specific mutations causing pituitary tumors. For example, Endeavor Biomedicines is developing an oral targeted therapeutic called EBV-101 for treating ACTH-secreting pituitary adenomas caused due to certain genetic alterations.
Market Trends
Growing adoption of targeted drug therapies – Targeted drug therapies such as Somatostatin analogues, Dopamine agonists, and mTOR inhibitors have gained widespread acceptance for controlling hormone hypersecretion in pituitary cancer. Drugs like Cabergoline and Pasireotide are becoming first-line treatment options.
Rising investment in development of novel targeted therapies – Numerous biopharma companies and research institutes are investing heavily in innovations to develop next-gen oral targeted drugs and hormone replacement therapies with improved safety profiles. For instance, Novartis and Camurus AB are jointly developing monthly Sandostatin LAR Depot for long-acting pituitary cancer treatment.
Market Opportunities
Untapped emerging markets – Emerging countries in Asia Pacific and Latin America remain largely untapped for pituitary cancer treatment due to lack of awareness and healthcare infrastructure challenges. This presents lucrative opportunities for global market players.
Combination therapy approaches – Combining targeted therapies, radiation, and hormone replacement is demonstrating encouraging results with fewer side effects. More R&D on optimized combination regimens can further improve patient outcomes.
Impact of COVID-19 on Pituitary Cancer Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Pituitary Cancer Market Size And Trends During the initial phase of the pandemic, stringent lockdowns and social distancing measures led to reduced access to hospitals for diagnosis and treatment. This resulted in delayed screening and diagnosis of pituitary cancer cases. The healthcare resources were also shifted to prioritize the treatment of COVID-19 patients. This further slowed down the medical procedures for pituitary cancer management. However, with advancement in telehealth and development of COVID-19 vaccines, the market is gradually recovering from mid-2021.
The focus is now on expanding access to essential care, screening programs, and investments in R&D for advanced treatment options. The growing awareness about pandemic’s indirect effects on chronic diseases and cancer is also driving the market growth. The future strategies need to focus on ensuring uninterrupted care, enhancing diagnostics, and prioritizing cancer treatment as the world gradually transitions to the endemic phase of COVID-19.
Geographical Regions with High Pituitary Cancer Market Value
North America accounts for the largest share of the global pituitary cancer market in terms of value. This is attributed to the rising incidence of pituitary tumors, well-established healthcare infrastructure, availability of advanced diagnostic and treatment options, and favorable reimbursement policies in the region. Within North America, the United States holds the major market share.
Fastest Growing Region for Pituitary Cancer Market
The Asia Pacific region is expected to witness the fastest growth in the pituitary cancer market during the forecast period. This is majorly due to the rapidly growing geriatric population, increasing awareness about pituitary disorders, improving diagnostic capabilities, and rising healthcare expenditures in countries such as China and India. The growing medical tourism industry is also supporting the regional market growth.
Get More Insights On, Pituitary Cancer Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
